BACKGROUND: We hypothesized that pediatric Hodgkin lymphoma (HL) survivors would have bone mineral density (BMD) deficits compared to their peers because of osteotoxic chemotherapy during the time of greatest BMD accretion. METHODS: We retrospectively reviewed records of HL survivors returning for follow-up between 1990 and 2002. Of the 133 eligible survivors, 109 who underwent quantitative computed tomography (QCT) comprised the study group. QCT-determined BMD Z-scores were correlated with patient characteristics and therapeutic exposures by Wilcoxon rank sum or Chi-square tests. Logistic regression models were used to explore risk factors for diminished BMD. RESULTS: The study cohort was half male (50.5%) and 85.3% reported their race as white. Participants were representative of all survivors potentially eligible for study, except that more study participants were female, had hypothyroidism, and had received cyclophosphamide. Median age at diagnosis was 15.1 years (range, 3.1-20.7 years); median time between diagnosis and QCT was 7.5 years (range, 5.0-12.4 years). The proportion of HL survivors with BMD below the mean did not significantly differ from the general population (P = 0.503). However, those with BMD -1.5 SD and BMD -2.0 SD or lower (14.7% and 7.3%, respectively) exceeded that in the general population (6.7% and 2.3%, respectively; P < 0.001 for both degrees of severity). Males, diagnosed at 14 years or older, were at 6.5 times higher risk than females (OR 95% CI: 1.24-34.14; P = 0.027) for BMD deficits. CONCLUSIONS: Overall, pediatric HL survivors had negligible BMD deficits. Male gender was associated with an increased risk of developing BMD deficits. Copyright 2008 Wiley-Liss, Inc.
BACKGROUND: We hypothesized that pediatric Hodgkin lymphoma (HL) survivors would have bone mineral density (BMD) deficits compared to their peers because of osteotoxic chemotherapy during the time of greatest BMD accretion. METHODS: We retrospectively reviewed records of HL survivors returning for follow-up between 1990 and 2002. Of the 133 eligible survivors, 109 who underwent quantitative computed tomography (QCT) comprised the study group. QCT-determined BMD Z-scores were correlated with patient characteristics and therapeutic exposures by Wilcoxon rank sum or Chi-square tests. Logistic regression models were used to explore risk factors for diminished BMD. RESULTS: The study cohort was half male (50.5%) and 85.3% reported their race as white. Participants were representative of all survivors potentially eligible for study, except that more study participants were female, had hypothyroidism, and had received cyclophosphamide. Median age at diagnosis was 15.1 years (range, 3.1-20.7 years); median time between diagnosis and QCT was 7.5 years (range, 5.0-12.4 years). The proportion of HL survivors with BMD below the mean did not significantly differ from the general population (P = 0.503). However, those with BMD -1.5 SD and BMD -2.0 SD or lower (14.7% and 7.3%, respectively) exceeded that in the general population (6.7% and 2.3%, respectively; P < 0.001 for both degrees of severity). Males, diagnosed at 14 years or older, were at 6.5 times higher risk than females (OR 95% CI: 1.24-34.14; P = 0.027) for BMD deficits. CONCLUSIONS: Overall, pediatric HL survivors had negligible BMD deficits. Male gender was associated with an increased risk of developing BMD deficits. Copyright 2008 Wiley-Liss, Inc.
Authors: S C Kaste; D Jones-Wallace; S R Rose; J M Boyett; R H Lustig; G K Rivera; C H Pui; M M Hudson Journal: Leukemia Date: 2001-05 Impact factor: 11.528
Authors: Jennifer Kelly; Timothy Damron; William Grant; Christopher Anker; Sean Holdridge; Susan Shaw; Jason Horton; Irene Cherrick; Joseph Spadaro Journal: J Pediatr Hematol Oncol Date: 2005-05 Impact factor: 1.289
Authors: Sarah S Donaldson; Melissa M Hudson; Kathleen R Lamborn; Michael P Link; Larry Kun; Amy Louise Billett; Karen C Marcus; Craig A Hurwitz; Jeffrey A Young; Nancy J Tarbell; Howard J Weinstein Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Alison M Friedmann; Melissa M Hudson; Howard J Weinstein; Sarah S Donaldson; Larry Kun; Nancy J Tarbell; Michael P Link Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Inge M van der Sluis; Marry M van den Heuvel-Eibrink; Karel Hählen; Eric P Krenning; Sabine M P F de Muinck Keizer-Schrama Journal: J Pediatr Date: 2002-08 Impact factor: 4.406
Authors: C Sklar; J Whitton; A Mertens; M Stovall; D Green; N Marina; B Greffe; S Wolden; L Robison Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 6.134
Authors: Jenneke E van Atteveld; Renée L Mulder; Marry M van den Heuvel-Eibrink; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; W Hamish Wallace; Louis S Constine; Claire E Higham; Sue C Kaste; Riitta Niinimäki; Sogol Mostoufi-Moab; Nathalie Alos; Danilo Fintini; Kimberly J Templeton; Leanne M Ward; Eva Frey; Roberto Franceschi; Vesna Pavasovic; Seth E Karol; Nadia L Amin; Lynda M Vrooman; Arja Harila-Saari; Charlotte Demoor-Goldschmidt; Robert D Murray; Edit Bardi; Maarten H Lequin; Maria Felicia Faienza; Olga Zaikova; Claire Berger; Stefano Mora; Kirsten K Ness; Sebastian J C M M Neggers; Saskia M F Pluijm; Jill H Simmons; Natascia Di Iorgi Journal: Lancet Diabetes Endocrinol Date: 2021-07-30 Impact factor: 44.867